Home / Health / FDA Approves New Blood-Cancer Drug Empliciti

FDA Approves New Blood-Cancer Drug Empliciti

The Food and Drug Administration pronounced Monday that it authorized Bristol-Myers Squibb Co.’s Empliciti to provide mixed myeloma, a form of blood cancer. The FDA authorized Empliciti to be used in multiple with dual other FDA-approved treatments, dexamethasone and Celgene Corp.’s Revlimid.

In a 646-participant clinical trial, those treated with a three-drug cocktail took longer to relapse and had a aloft possibility of growth decline than…

Article source: http://www.wsj.com/articles/fda-approves-new-blood-cancer-drug-empliciti-1448901505

InterNations.org